M. Cavallini, M. Papagni5. Altman DG, Bland JM. Quartiles, quintiles, centiles, andother quantiles. BMJ 1994; 309 (6960):9966. Scott PJ, Huskisson EC. Measurement of functionalcapacity with visual analogue scales. Rheumatol Rehabil1977;16:257-97. Torri C. Reference Values of Soft Parameters. Internaldata, Research and Development, Callegari S.p.A.8. Sparavigna A, Gallato R, Parenzan P, D’Este P, Pepe P,Flori L, Andreassi L. Studio pilota <strong>per</strong> la determinazionedei range di normalità di sebo, idratazione e pH cutaneimediante “Bioskin Tester”. G Ital Dermatol Venereol 1993;28; V-X9. Rathbone MP, Christjanson L, Deforge S, Deluca B,Gysbers JW, Hindley S, Jovetich M, Middlemiss P, Takhal S.Extracellular purine nucleosides stimulate cell division andmorphogenesis: pathological and physiological implications.Med Hypotheses 1992; 37:232-4010. Rathbone MP, Middlemiss PJ, Gysbers JW, DeForge S,Costello P, Del Maestro RF. Purine nucleosides andnucleotides stimulate proliferation of a wide range of celltypes. In Vitro Cell Dev Biol 1992; 28A:529-3611. Montesinos MC, Gadangi P, Longaker M, Sung J, LevineJ, Nilsen D, Reibman J, Li M, Jiang CK, Hirschhorn R,Recht PA, Ostad E, Levin RI, Cronstein BN. Wound healingis accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med 1997; 186:1615-2012. Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.Adenosine A2A receptor agonists promote more rapidwound healing than recombinant human platelet-derivedg rowth factor (Becaplermin gel). Inflammation 2002;26:19-2413. Sini P, Denti A, Cattarini G, Daglio M, Tira ME,Balduini C. Effect of polydeoxyribonucleotides on humanfibroblasts in primary culture. Cell Biochem Funct 1999;17: 107-1414. Castelpietra R, Massirone A, Heydecker FC. Il polidesossiribonucleotide(PDRN) nel programma di ringiovanimentodel viso. 3° Congresso Nazionale di MedicinaEstetica 2001; Milano 12-14 Ottobre, Abstract Book 3-415. Cavallini M. Biorevitalization and Cosmetic Surgery ofthe Face: Synergies of Action. J Appl Cosmetol 2004; 22:125-13216. Cattarini G. Mechanism of action of a polydeoxiribonucleotide(PDRN): an anti age drug for tissue revitalization.WorldAnti Aging Conference 2005; MonteCarlo10-12 March, abstract book 5117. Masnada MC, Lodi A, Betti R, Cattaneo M.Sull’impiego di un estratto di placenta <strong>per</strong> via intradermicain lesioni acneiche- cicatriziali. La Medicina Estetica 1984;11:69-7218. Rantuccio F, Coviello C, Conte A. Impiego di polidesossiribonucleatidee glucosoaminoglicani <strong>per</strong> via mesoterapicanel trattamento di esiti cicatriziali depressi. La MedicinaEstetica 1989; 13:27-3119. Rossi E. Come cancellare le smagliature. Impiego di unestratto di placenta intralesionale nelle smagliature cutanee.Diagnosi & Terapia 1987; 8:5-620. Follador E. Protocollo terapeutico con PDRN iniettabilee acido glicolico nel trattamento di striae distensae(smagliature) ed esiti cicatriziali depressi di natura postacneica.Es<strong>per</strong>ienza <strong>per</strong>sonale e primi risultati. XVIIICongresso Nazionale della Società di Medicina Estetica, Lamedicina Estetica. 1997; 21:33-3421. Cavallini M, Caputo MG, Forte R, Girri E, OskarbskiGV, Calmieri IP, Romagnoli M, Trainotti C. Multicenterstudy on striae treatment with TCA and PDRN. LaMedicina Estetica 2005; 29:27222. Lehninger AL. Biochimica - Le basi molecolari dellastruttura e della funzione cellulare. Zanichelli Ed., II Ed,670-67123. Blackburn GM, Gait MJ. Nucleic acids in chemistry andbiology. lrl Press at Oxford University Press Ed., 199024. Cattarini G. Radiazioni solari e polinucleotidi.Dermatologia Ambulatoriale 2003; Anno XI, n°1, gennaiomarzo,53-5525. Belletti S, Uggeri J, Gatti R, Orlandini G, Govoni P,Scandroglio R, Guizzardi S. Pololed deoxyribonucleotidespolymers promote DNA repair after UVB damage inhuman dermal fibroblasts. It J Anat Embriol 9/2006; 111(Suppl 2):1926. Stanghellini E, De Aloe G, Carcagni ML, Cattarini G,Fimiani M. Evaluation of antioxidant activity of a topicalcream. Fifth International Workshop on Photodermatology2003; Sabaudia (LT) 30-31 Maggio27. Thione A. High-concentration polynucleotides one yearof ex<strong>per</strong>ience in anti aging treatments. International MasterCourse on Aging Skin – IMCAS <strong>2007</strong>; 11-13 January, Paris28. Moro L, Bertolini S. I Polinucleotidi: la nuova frontieradella bioristrutturazione cutanea. La Medicina Estetica2006; 30:3929. Forti M, Cavallini M. Use of polynucleotides in thetreatment of stretch marks. 8th International Congress ofAesthetic Medicine 2006; Milan 12-15 October, abstractbook 16532Journal of Plastic Dermatology <strong>2007</strong>; 3, 3
Vitiligo Activity Index, a new activityevaluation index for bilateralvitiligo vulgarisGiovanni MenchiniClaudio ComacchiSU M M A R YVitiligo Activity Index,a new activity evaluation indexfor bilateral vitiligo vulgarisVitiligo vulgaris is an autoimmune disease with fairly unpredictable clinicalprogress. The population incidence worldwide is 1% without significant associationswith race or sex. To this day no prognostic index exists and no standard symptomaticreference scheme has been established to evaluate the clinical course of the disease,in order to point dermatologists toward an appropriate therapeutic path and to guideresearchers approaching new treatments.In this pa<strong>per</strong> we present a new evaluation index called Vitiligo Activity Index, aneasy tool that enables dermatologists to relate the disease activity to a precisenumerical value.KE Y W O R D S: Vitiligo Activity Index, Vi t i l i g oG.I.S.V.(Gruppo Italiano di Studio e Terapiadella Vitiligine), Pisa e Firenze, ItaliaI ntroductionVitiligo Vulgaris Bilateral (VVB) is adisease that causes the formation of ipochromic/achromicpatches of skin and its pathogenesisis almost certainly autoimmune (1-5).Conventional therapy consists mainly ofimmunosuppressant and ultraviolet B narrowband phototherapy (6).Similarly to other autoimmune diseases, VVBclinical course is extremely variable, alternating<strong>per</strong>iods of progression, stationary states and afew spontaneous events of repigmentation (7).To this day, VVB course evaluation was almostexclusively based upon the patient’s own observationand on the description of the patient’simpressions to the dermatologist.One of the major causes of therapeutic failure isthe lack of prognostic indexes and lab-baseddata that describe the actual activity conditionof VVB.In order to make up for this deficiency, weidentified morphological skin signs that arepathognomonic of a recent disappearing ofmelanocytes or of recent re p i g m e n t a t i o n .Some of the morphological signs identified inthis study have already been described in otherscientific pa<strong>per</strong>s (such as follicle repigmentation);other signs are described for the first timein this article.An exhaustive study of morphology in vitiligopatches led us to the conclusion that they areactually interrelated with vitiligo activity andprogress.On the basis of our observation data, derivedfrom a ten year long ex<strong>per</strong>ience in vitiligoresearch and therapy, we suggest the introductionof an index called Vitiligo Activity Index(VAI), in order to quantify and describe thelevel and nature of activity of the disease.In our opinion, VAI quantifies the diseaseaggressiveness or repigmentation and thereforeallows a more appropriate therapy choice and arapid evaluation of the therapy progress.Our goal is the creation of an index that can beeasily consulted and understood by patientsand doctors alike and that can lead to a quickevaluation of the subject’s dermatosis.Journal of Plastic Dermatology <strong>2007</strong>; 3, 3 35
- Page 1: Vol. 3, n. 3, September-December 20
- Page 4: L’istopatologia ed il foto-invecc
- Page 10: P. Filecciaammesso nelle formulazio
- Page 13 and 14: A. Sparavigna A, R. Forte, F.S. Dio
- Page 15 and 16: A. Sparavigna A, R. Forte, F.S. Dio
- Page 17 and 18: A. Sparavigna A, R. Forte, F.S. Dio
- Page 20 and 21: M. Cavallini, M. Papagnitaining lon
- Page 22 and 23: M. Cavallini, M. PapagniSkin hydrat
- Page 26 and 27: G. Menchini, C. ComacchiM ethodsO b
- Page 28 and 29: G. Menchini, C. Comacchimentation,
- Page 30 and 31: Impiego di lamine autoadesivedi pol
- Page 32 and 33: Impiego di lamine autoadesive di po
- Page 34 and 35: Impiego di lamine autoadesive di po
- Page 36 and 37: Efficacia, tollerabilità ed accett
- Page 38 and 39: Efficacia, tollerabilità ed accett
- Page 40 and 41: Efficacia, tollerabilità ed accett
- Page 42 and 43: D. AnconaGli studi sulla citotossic
- Page 44 and 45: D. AnconaPRIMADOPOFigura 2. Pazient
- Page 46 and 47: L.Scuderi, L. Francesconi, F. Dinot
- Page 48 and 49: L.Scuderi, L. Francesconi, F. Dinot
- Page 50 and 51: E. Perosino12Figura 1.Lesione macul
- Page 52 and 53: Irsutismo:trattamento con eflorniti
- Page 54 and 55: Irsutismo: trattamento con eflornit
- Page 56 and 57: Irsutismo: trattamento con eflornit
- Page 58 and 59: Irsutismo: trattamento con eflornit
- Page 60 and 61: Irsutismo: trattamento con eflornit
- Page 62 and 63: Irsutismo: trattamento con eflornit
- Page 64 and 65: Una molecola classicain una nuova v
- Page 66 and 67: Microcircolo, cute e antocianosidiA
- Page 68 and 69: Microcircolo, cute e antocianosidiL
- Page 70 and 71: Microcircolo, cute e antocianosidiG
- Page 72 and 73: Microcircolo, cute e antocianosidiC
- Page 78:
struzioni agli AutoriIObiettivo del